Pricing Log in Create free account

DiaMedica Therapeutics, Inc. (DMAC) vs Puma Biotechnology, Inc. (PBYI)

DiaMedica Therapeutics, Inc. and Puma Biotechnology, Inc. are both Biotechnology companies. DiaMedica Therapeutics, Inc. and Puma Biotechnology, Inc. are of similar size ($504.3M and $487.5M). DiaMedica Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Puma Biotechnology, Inc. trades at 15.3×. Puma Biotechnology, Inc. has the higher net margin (11.6% vs 0.00%) and the higher return on invested capital (42.6% vs 0.00%). Across the 13 metrics below, Puma Biotechnology, Inc. leads on 12 and DiaMedica Therapeutics, Inc. on 1.

Valuation

Metric DMAC PBYI Biotechnology median
P/E n/m 15.31 10.60
P/S n/m 1.82 9.40
P/B 13.30 3.04 2.13
Price to free cash flow n/m 14.74 25.18
EV/EBITDA n/m 8.54 0.66
EV/Sales n/m 1.51 9.02
Earnings yield (7.61%) 6.53% (32.88%)
Free cash flow yield (6.19%) 6.78% (23.13%)

Profitability

Metric DMAC PBYI Biotechnology median
Gross margin 0.00% 74.83% 68.51%
Operating margin 0.00% 13.16% 0.00%
Net margin 0.00% 11.55% 0.00%
Free cash flow margin 0.00% 17.79% 0.00%
Return on equity (114.62%) 21.97% (51.96%)
Return on assets (98.18%) 13.78% (46.06%)
Return on invested capital 0.00% 42.61% 0.00%

Growth

Metric DMAC PBYI Biotechnology median
Revenue growth (TTM) — (2.86%) 6.76%
EPS growth (last fiscal year) (16.67%) (1.61%) 29.88%
Revenue growth, 5-year CAGR — 0.29% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DMAC PBYI Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.72 2.91 4.97
Net debt to EBITDA 1.70 (1.60) 1.01

Dividend

Metric DMAC PBYI Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric DMAC PBYI Biotechnology median
Market cap 487.49m 504.33m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack